Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma

Shigeru Ueda, Ken Shirabe, Kazutoyo Morita, Kenji Umeda, Hiroto Kayashima, Hideaki Uchiyama, Yuji Soejima, Akinobu Taketomi, Yoshihiko Maehara

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Excision repair cross-complementation group 1 (ERCC1) is one of the key enzymes in DNA repair. This study was designed to investigate the correlation between ERCC1 expression and chemosensitivity to cisplatin (CDDP) in patients with hepatocellular carcinoma (HCC). Methods: Eighty-seven HCC samples were analyzed by immunohistochemistry for ERCC1 and chemosensitivity was assessed by the succinate dehydrogenase inhibition (SDI) test for four anti-cancer agents, including CDDP. The ERCC1 expression was examined in HCC cell lines. ERCC1 siRNA was transfected to PLC/RPF/5 to investigate the correlation of ERCC1 expression and CDDP sensitivity. Results: ERCC1 expression was observed in 33% of nuclei in immunohistochemical examination. Patients were divided into two groups as follows: ERCC1 high expression group (n = 43): more than 33% of the nuclei were stained; ERCC1 low expression group (n = 44): 33% or fewer of the nuclei were stained. Tumor size of low expression group was larger than that in the high expression group (p = 0.02). The succinic dehydrogenase (SD) activity only for CDDP was significantly higher in the high expression group than that in the low expression group (p = 0.02). An increased expression of ERCC1 was shown by immunohistochemical and Western blot analyses in PLC/RPF/5. ERCC1 expression was inhibited by ERCC1 siRNA transfection and the LC50 value (nM) of CDDP was reduced from 25.7 to 12.5 (p = 0.01). Conclusions: Increased ERCC1 expression is associated with CDDP resistance in HCC specimens and cell lines. Therefore, immunohistochemical analysis for resected HCC tissues may be a useful predictor for the effectiveness of adjuvant chemotherapy, using CDDP.

Original languageEnglish
Pages (from-to)1204-1211
Number of pages8
JournalAnnals of Surgical Oncology
Volume18
Issue number4
DOIs
Publication statusPublished - Apr 1 2011

Fingerprint

DNA Repair
Cisplatin
Hepatocellular Carcinoma
Succinate Dehydrogenase
Small Interfering RNA
DNA Repair Enzymes
Cell Line
Adjuvant Chemotherapy
Transfection
Neoplasms
Western Blotting
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Ueda, S., Shirabe, K., Morita, K., Umeda, K., Kayashima, H., Uchiyama, H., ... Maehara, Y. (2011). Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma. Annals of Surgical Oncology, 18(4), 1204-1211. https://doi.org/10.1245/s10434-010-1414-4

Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma. / Ueda, Shigeru; Shirabe, Ken; Morita, Kazutoyo; Umeda, Kenji; Kayashima, Hiroto; Uchiyama, Hideaki; Soejima, Yuji; Taketomi, Akinobu; Maehara, Yoshihiko.

In: Annals of Surgical Oncology, Vol. 18, No. 4, 01.04.2011, p. 1204-1211.

Research output: Contribution to journalArticle

Ueda, S, Shirabe, K, Morita, K, Umeda, K, Kayashima, H, Uchiyama, H, Soejima, Y, Taketomi, A & Maehara, Y 2011, 'Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma', Annals of Surgical Oncology, vol. 18, no. 4, pp. 1204-1211. https://doi.org/10.1245/s10434-010-1414-4
Ueda, Shigeru ; Shirabe, Ken ; Morita, Kazutoyo ; Umeda, Kenji ; Kayashima, Hiroto ; Uchiyama, Hideaki ; Soejima, Yuji ; Taketomi, Akinobu ; Maehara, Yoshihiko. / Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma. In: Annals of Surgical Oncology. 2011 ; Vol. 18, No. 4. pp. 1204-1211.
@article{6ea04b35f6fc4ab090b35509e948976f,
title = "Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma",
abstract = "Background: Excision repair cross-complementation group 1 (ERCC1) is one of the key enzymes in DNA repair. This study was designed to investigate the correlation between ERCC1 expression and chemosensitivity to cisplatin (CDDP) in patients with hepatocellular carcinoma (HCC). Methods: Eighty-seven HCC samples were analyzed by immunohistochemistry for ERCC1 and chemosensitivity was assessed by the succinate dehydrogenase inhibition (SDI) test for four anti-cancer agents, including CDDP. The ERCC1 expression was examined in HCC cell lines. ERCC1 siRNA was transfected to PLC/RPF/5 to investigate the correlation of ERCC1 expression and CDDP sensitivity. Results: ERCC1 expression was observed in 33{\%} of nuclei in immunohistochemical examination. Patients were divided into two groups as follows: ERCC1 high expression group (n = 43): more than 33{\%} of the nuclei were stained; ERCC1 low expression group (n = 44): 33{\%} or fewer of the nuclei were stained. Tumor size of low expression group was larger than that in the high expression group (p = 0.02). The succinic dehydrogenase (SD) activity only for CDDP was significantly higher in the high expression group than that in the low expression group (p = 0.02). An increased expression of ERCC1 was shown by immunohistochemical and Western blot analyses in PLC/RPF/5. ERCC1 expression was inhibited by ERCC1 siRNA transfection and the LC50 value (nM) of CDDP was reduced from 25.7 to 12.5 (p = 0.01). Conclusions: Increased ERCC1 expression is associated with CDDP resistance in HCC specimens and cell lines. Therefore, immunohistochemical analysis for resected HCC tissues may be a useful predictor for the effectiveness of adjuvant chemotherapy, using CDDP.",
author = "Shigeru Ueda and Ken Shirabe and Kazutoyo Morita and Kenji Umeda and Hiroto Kayashima and Hideaki Uchiyama and Yuji Soejima and Akinobu Taketomi and Yoshihiko Maehara",
year = "2011",
month = "4",
day = "1",
doi = "10.1245/s10434-010-1414-4",
language = "English",
volume = "18",
pages = "1204--1211",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma

AU - Ueda, Shigeru

AU - Shirabe, Ken

AU - Morita, Kazutoyo

AU - Umeda, Kenji

AU - Kayashima, Hiroto

AU - Uchiyama, Hideaki

AU - Soejima, Yuji

AU - Taketomi, Akinobu

AU - Maehara, Yoshihiko

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Background: Excision repair cross-complementation group 1 (ERCC1) is one of the key enzymes in DNA repair. This study was designed to investigate the correlation between ERCC1 expression and chemosensitivity to cisplatin (CDDP) in patients with hepatocellular carcinoma (HCC). Methods: Eighty-seven HCC samples were analyzed by immunohistochemistry for ERCC1 and chemosensitivity was assessed by the succinate dehydrogenase inhibition (SDI) test for four anti-cancer agents, including CDDP. The ERCC1 expression was examined in HCC cell lines. ERCC1 siRNA was transfected to PLC/RPF/5 to investigate the correlation of ERCC1 expression and CDDP sensitivity. Results: ERCC1 expression was observed in 33% of nuclei in immunohistochemical examination. Patients were divided into two groups as follows: ERCC1 high expression group (n = 43): more than 33% of the nuclei were stained; ERCC1 low expression group (n = 44): 33% or fewer of the nuclei were stained. Tumor size of low expression group was larger than that in the high expression group (p = 0.02). The succinic dehydrogenase (SD) activity only for CDDP was significantly higher in the high expression group than that in the low expression group (p = 0.02). An increased expression of ERCC1 was shown by immunohistochemical and Western blot analyses in PLC/RPF/5. ERCC1 expression was inhibited by ERCC1 siRNA transfection and the LC50 value (nM) of CDDP was reduced from 25.7 to 12.5 (p = 0.01). Conclusions: Increased ERCC1 expression is associated with CDDP resistance in HCC specimens and cell lines. Therefore, immunohistochemical analysis for resected HCC tissues may be a useful predictor for the effectiveness of adjuvant chemotherapy, using CDDP.

AB - Background: Excision repair cross-complementation group 1 (ERCC1) is one of the key enzymes in DNA repair. This study was designed to investigate the correlation between ERCC1 expression and chemosensitivity to cisplatin (CDDP) in patients with hepatocellular carcinoma (HCC). Methods: Eighty-seven HCC samples were analyzed by immunohistochemistry for ERCC1 and chemosensitivity was assessed by the succinate dehydrogenase inhibition (SDI) test for four anti-cancer agents, including CDDP. The ERCC1 expression was examined in HCC cell lines. ERCC1 siRNA was transfected to PLC/RPF/5 to investigate the correlation of ERCC1 expression and CDDP sensitivity. Results: ERCC1 expression was observed in 33% of nuclei in immunohistochemical examination. Patients were divided into two groups as follows: ERCC1 high expression group (n = 43): more than 33% of the nuclei were stained; ERCC1 low expression group (n = 44): 33% or fewer of the nuclei were stained. Tumor size of low expression group was larger than that in the high expression group (p = 0.02). The succinic dehydrogenase (SD) activity only for CDDP was significantly higher in the high expression group than that in the low expression group (p = 0.02). An increased expression of ERCC1 was shown by immunohistochemical and Western blot analyses in PLC/RPF/5. ERCC1 expression was inhibited by ERCC1 siRNA transfection and the LC50 value (nM) of CDDP was reduced from 25.7 to 12.5 (p = 0.01). Conclusions: Increased ERCC1 expression is associated with CDDP resistance in HCC specimens and cell lines. Therefore, immunohistochemical analysis for resected HCC tissues may be a useful predictor for the effectiveness of adjuvant chemotherapy, using CDDP.

UR - http://www.scopus.com/inward/record.url?scp=79955867544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955867544&partnerID=8YFLogxK

U2 - 10.1245/s10434-010-1414-4

DO - 10.1245/s10434-010-1414-4

M3 - Article

C2 - 21076943

AN - SCOPUS:79955867544

VL - 18

SP - 1204

EP - 1211

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -